Ghosh A K, Mellor M, Prendiville J, Thatcher N
Immunology Laboratory, Paterson Institute for Cancer Research, Manchester, UK.
Br J Cancer. 1990 Mar;61(3):471-4. doi: 10.1038/bjc.1990.104.
Natural killer (NK) cell activity and lymphokine activated killer (LAK) cell cytotoxicity were measured in patients receiving recombinant interleukin 2 (rIL-2) and flavone acetic acid (FAA) for treatment of progressing metastatic melanoma. NK activity was increased in 23 of 26 patients and LAK activity induced in 13 of 26 patients. However, levels of cytotoxicity in the present study were not significantly greater than a previous study using rIL-2 alone. LAK cell precursors demonstrated by in vitro incubation of pretreatment lymphocytes with IL-2 and subsequent cytotoxicity were no different in the patients compared to normal controls. Analysis of cell surface phenotypes failed to reveal any significant changes in the cell populations examined, including IL-2R and Leu 19. Although five patients had tumour response, one being complete, there was no correlation with the immunological parameters examined.
在接受重组白细胞介素2（rIL-2）和黄酮乙酸（FAA）治疗进展期转移性黑色素瘤的患者中，检测了自然杀伤（NK）细胞活性和淋巴因子激活的杀伤（LAK）细胞细胞毒性。26例患者中有23例NK活性增加，26例患者中有13例诱导出LAK活性。然而，本研究中的细胞毒性水平并不显著高于先前单独使用rIL-2的研究。通过预处理淋巴细胞与IL-2体外孵育及随后的细胞毒性所证实的LAK细胞前体，在患者与正常对照之间并无差异。对细胞表面表型的分析未能揭示所检测细胞群体的任何显著变化，包括IL-2R和Leu 19。尽管有5例患者出现肿瘤反应，其中1例完全缓解，但与所检测的免疫参数并无相关性。
